Dr Strick Woods
0 Emerging Treatments
Learn about treatments beyond the ones offered by your doctor.
Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by diarrhea and
abdominal pain. Treatments include:
o 5-aminosalicylates, also known as 5-ASA (e.g. Asacol, Pentasa, Mezavant, Salofalk, and
o Steroids (e.g. Entocort, prednisone)
o Immunomodulators (e.g. Imuran, Purinethol, Rheumatrex)
o Biologics (e.g. Remicade, Humira, Entyvio)
5-ASAs are the most commonly prescribed drug class for CD however there is uncertainty regarding their effectiveness for treating CD. Despite this, doctors continue to prescribe a potentially ineffective treatment which, aside from costs ($23M in Canada/year), possibly delays the use of more effective treatments that could reduce the risk of preventable complications in patients, such as surgery.
The STATIC study is trying to determine if patients who stop taking their 5-ASA do no worse than those who continue taking their 5-ASA. Participants will be monitored for complications, surgeries or hospitalizations. The results of this study have potential to improve the lives of patients, change physician prescribing practice, and reduce health care costs.
This study is evaluating how effective two diets are the for treatment of Crohn's disease: the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD). Both diets have been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and inflammation in the bowel.
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.
This study is evaluating the treatment of ulcerative colitis with hyperbaric oxygen therapy. Recent small studies have shown hyperbaric oxygen can treat ulcerative colitis however researchers don't understand how it does it. This study will look at markers in the body to determine how hyperbaric oxygen treats ulcerative colitis.
Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira, etc.).
Discover the leading researchers for your condition.
Discover the top Crohn's and colitis clinics in your area offering emerging treatments provided by leading researchers in their field.
World-class researchers are working together to find new, safer alternatives to current on-the-market medications. Find emerging treatment options in your city.
Take a proactive approach to your treatment. Know your options and learn more about the ones applicable to you.
Finding a treatment that works for you is essential to living a full life. Work with highly esteemed Doctors at advanced facilities. Many emerging treatment options come at no cost and may even offer compensation and travel reimbursement.